Hepatitis C - References

Citations

  1. Terrault NA, et al. (2013). Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV Partners Study. Hepatology, 57(3): 881-889.

  2. Dienstag JL (2010). Chronic viral hepatitis. In GL Mandell et al., eds., Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed., vol. 1, pp. 1593-1670. Philadelphia: Churchill Livingstone Elsevier.

  3. Flamm SL (2003). Chronic hepatitis C virus infection. JAMA, 289(18): 2413-2417.

  4. Smith BD, et al. (2012). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR, 61(RR-4): 1-32. Available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm.

  5. U.S. Preventive Services Task Force (2013). Screening for Hepatitis C Virus Infection in Adults: Recommendation Statement. Available online: http://www.uspreventiveservicestaskforce.org/uspstf/uspshepc.htm.

  6. Wiegand J, et al. (2006). Early monotherapy with pegylated interferon alfa-2b for acute hepatitis C infection: The HEP-NET Acute HCV-II Study. Hepatology, 43(2): 250-256.

  7. Centers for Disease Control and Prevention (2012). Hepatitis C FAQs for health professionals. Available online: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm.

  8. Ward RP, et al. (2004). Management of hepatitis C: Evaluating suitability for drug therapy. American Family Physician, 69(6): 1429-1438.

  9. U.S. Food and Drug Administration (2009). Consumer advisory: Kava-containing dietary supplements may be associated with severe liver injury. Available online: http://www.fda.gov/Food/ResourcesForYou/Consumers/ucm085482.htm.

  10. National Center for Complementary and Alternative Medicine (2012). Get the Facts: Hepatitis C: A Focus on Herbal Supplements (NCCAM Publication No. D422). Washington, DC: U.S. National Institutes of Health. Available online: http://nccam.nih.gov/health/hepatitisc/hepatitiscfacts.htm.

  11. Fried MW, et al. (2012). Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial. JAMA, 308(3): 274-282.

Other Works Consulted

  • Centers for Disease Control and Prevention (2005). Guidelines for Viral Hepatitis Surveillance and Case Management. Available online: http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm.

  • Craxi A, Licata A (2006). Acute hepatitis C: In search of the optimal approach to cure. Hepatology, 43(2): 221-224.

  • Everson GT, et al. (2008). Quantitative tests of liver function measure hepatic improvement after sustained virological response: Results from the HALT-C trial. Alimentary Pharmacology and Therapeutics, 29(5): 589-601.

  • Mack CL, et al. (2012). NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. Journal of Pediatric Gastroenterology and Nutrition, 54(6): 838-855.

  • Maylin S, et al. (2008). Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology, 135(3): 821-829.

  • Mohsen A, Norris S (2010). Hepatitis C (chronic), search date April 2008. Online version of BMJ Clinical Evidence: http://www.clinicalevidence.com.

  • World Health Organization (2014). Guidelines for the screening, care and treatment of persons with hepatitis C infection. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1. Accessed May 15, 2014.

WebMD Medical Reference from Healthwise
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.© 1995-2015 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.